Oakridge International FY26 Results Show Healthcare Technology Growth and Return to Profitability

Highlights

• Oakridge International returned to profitability in FY26 as healthcare technology sales and business development activities supported revenue growth.
• The company expanded its nurse call, IoT and assisted living technology capabilities across healthcare sectors.
• Stronger cash generation and product development initiatives supported the company’s long-term healthcare technology strategy.

FY26 Performance Improves on Healthcare Technology Growth

Oakridge International Limited (ASX: OAK) released its FY26 Annual Report on 24 August 2026, covering the financial year ended 30 June 2026. Revenue from ordinary operations increased to AU$3.45 million in FY26, reflecting a 42% year-on-year improvement driven by stronger business activity and sales growth. Profit attributable to shareholders reached AU$109,171, recovering from a loss of AU$128,795 in FY25.

The improved result was supported by increased sales activity and stronger business development initiatives. Oakridge continued focusing on delivering healthcare technology solutions, including nurse call hardware and software systems for hospitals, aged care, disability care and supported independent living environments.

Product Innovation Strengthens Market Position

During FY26, Oakridge progressed development of its healthcare technology platform, including enhancements to the NuCaMS and NuCaMS Enterprise solutions. The company improved reporting capabilities, scalability, system integration and performance while completing development work on RTLS call points and resident pendant technology.

The company also advanced cloud-based integration, authentication features, reporting functions and mobile application development. These initiatives are designed to support broader adoption of connected healthcare solutions and improve operational efficiency for care providers.

Sales Pipeline and Healthcare Expansion Continue

Oakridge delivered projects across multiple regions and care facilities during the year, with growth supported by direct sales and expanding partner channels. The company progressed installations, commissioning activities and integrated technology deployments across assisted living environments.

The company also strengthened relationships with healthcare providers, aged care operators and technology partners through nurse call upgrades, wireless systems, RTLS deployments and multi-site programs. Management expects existing channel activity and project conversion opportunities to support revenue growth into FY27.

Financial Position Strengthens

Oakridge ended FY26 with cash and cash equivalents of AU$637,641, compared with AU$468,939 in the prior year. Total assets increased to AU$2.12 million, while net assets improved to AU$1.36 million from AU$902,246.

Operating cash flow improved, with net cash generated from operating activities reaching AU$127,028, compared with an outflow of AU$358,457 in FY25.

Outlook

Oakridge remains focused on expanding its healthcare technology platform, developing AI-enabled capabilities and pursuing opportunities within connected care solutions. The company expects ageing population trends, increasing demand for care technology and growth in healthcare infrastructure investment to support long-term market opportunities.

With a growing product suite, improving financial performance and continued investment in technology development, Oakridge aims to strengthen its position in the healthcare technology sector.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au